SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001624422-23-000044
Filing Date
2023-09-26
Accepted
2023-09-26 15:01:39
Documents
66
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 6-K eryp-20230630.htm   iXBRL 6-K 150450
2 EX-99.1 eryp-20230630_d2.htm   iXBRL EX-99.1 997005
3 EX-99.2 ex-992phxm_6xkx09212023.htm EX-99.2 64546
9 imagea.jpg GRAPHIC 7189
  Complete submission text file 0001624422-23-000044.txt   7664524

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT eryp-20230630.xsd EX-101.SCH 82309
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT eryp-20230630_cal.xml EX-101.CAL 98104
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT eryp-20230630_def.xml EX-101.DEF 346721
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eryp-20230630_lab.xml EX-101.LAB 751432
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT eryp-20230630_pre.xml EX-101.PRE 498540
60 EXTRACTED XBRL INSTANCE DOCUMENT eryp-20230630_htm.xml XML 1399849
Mailing Address 60 AVENUE ROCKEFELLER BATIMENT ADENINE LYON I0 69008
Business Address 60 AVENUE ROCKEFELLER BATIMENT ADENINE LYON I0 69008 011-33-4-78-74-44-38
PHAXIAM Therapeutics S.A. (Filer) CIK: 0001624422 (see all company filings)

IRS No.: 000000000 | State of Incorp.: I0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38281 | Film No.: 231280115
SIC: 2836 Biological Products, (No Diagnostic Substances)